Streptozotocin revisited: Pharmacological determinants supporting new scheduling strategies in neuroendocrine tumours
Cancer Treatment Reviews · 2026
DOI: 10.1016/j.ctrv.2026.103140 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2026. Verfasst von Nicola Fazio und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Streptozocin, Antineoplastic Agents, Alkylating, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: ESTEVE.
Abstract (Originalsprache)
Streptozotocin (STZ) remains a potentially effective chemotherapeutic agent for pancreatic neuroendocrine tumours, more than five decades after its initial use. Despite its longstanding clinical application, STZ dosing regimens have traditionally been driven by empirical practice rather than by pharmacokinetic or pharmacodynamic rationale. Recent advances in understanding its molecular mechanism of action, selective uptake via the glucose transporter type 2 transporter, and DNA-methylating properties provide a solid foundation for revisiting its therapeutic role and optimising its scheduling. This review outlines the key pharmacological features of STZ, including its rapid systemic clearance, narrow volume of distribution, and renal elimination, all of which support the use of short intravenous infusions and fractionated schedules to minimise nephrotoxicity while maintaining efficacy. Comparative insights with temozolomide highlight the unique delivery and tissue tropism advantages of STZ, particularly in pancreatic neuroendocrine tumours. In addition, emerging biomarkers, such as O⁶-methylguanine-DNA methyltransferase deficiency and mismatch repair status, may help refine patient selection for STZ-based chemotherapy. Clinical data from classical and modern regimens, such as those combining STZ with 5-fluorouracil or capecitabine, suggest sustained disease control in well-selected patients. The potential for biomarker-guided strategies and pharmacology-informed protocols supports a contemporary repositioning of STZ in neuroendocrine oncology. Rational redesign of dosing, improved toxicity management, and integration with personalised medicine may revitalise the clinical utility of this historically valuable agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
- Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), IRCCS, Milan, Italy. Electronic address: francesca.spada@ieo.it.
- Departmental Faculty of Medicine, Saint Camillus International University of Health and Medical Sciences, Rome, Italy.
- Department of Oncology and Hemato-Oncology, University of Milano "La Statale", Milan, Italy.
Förderung
- ESTEVE
Zitieren
APA
Fazio, N., Spada, F., Benini, L., Mulargiu, C., Del Re, M., & Danesi, R. (2026). Streptozotocin revisited: Pharmacological determinants supporting new scheduling strategies in neuroendocrine tumours. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2026.103140
Vancouver
Fazio N, Spada F, Benini L, Mulargiu C, Del Re M, Danesi R. Streptozotocin revisited: Pharmacological determinants supporting new scheduling strategies in neuroendocrine tumours. Cancer Treatment Reviews. 2026. doi:10.1016/j.ctrv.2026.103140
BibTeX
@article{Fazio2026,
author = {Fazio, Nicola and Spada, Francesca and Benini, Lavinia and Mulargiu, Cristiana and Del Re, Marzia and Danesi, Romano},
title = {Streptozotocin revisited: Pharmacological determinants supporting new scheduling strategies in neuroendocrine tumours},
journal = {Cancer Treatment Reviews},
year = {2026},
doi = {10.1016/j.ctrv.2026.103140}
}
EUVIMED